Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4726216 | 0.90 | KDM4E (0.78) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL13816846 | 0.86 | KDM4E (0.76) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL6379762 | 0.82 | KDM4E (0.78) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL17320354 | 0.80 | KDM4E (0.85) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL27236981 | 0.78 | KMT2A (0.72) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL18093460 | 0.78 | ALDH1A1 (0.81) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL6383092 | 0.77 | ALDH1A1 (0.70) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL4730776 | 0.77 | ALDH1A1 (0.70) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL8036388 | 0.76 | KMT2A (0.74) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL6385452 | 0.76 | KDM4E (0.57) | KDM4EALDH1A1KMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827421-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-1827421-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-1943224-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1943224-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-07-27 | — | — | EP | disclosed |
| US-7923568-B2 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923568-B2 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923568-B2 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100168188-A1 | Estrogen Receptor Modulators | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-20100168188-A1 | Estrogen Receptor Modulators | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-20100168188-A1 | Estrogen Receptor Modulators | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-7511152-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511152-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1943224-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070265318-A1 | 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265318-A1 | 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| US-20070265318-A1 | 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| EP-1827421-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007089291-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089291-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006062876-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265318-A1 | 6-(trifluoromethyl)-3,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(8H)-one; uterine fibroid disease, hot flashes, urogenital disorders, inflammation; improved metabolic profile | GPER1, ESRRA, HSD17B11 | KDM4E 3282/4885ALDH1A1 1111/4885KMT2A 1342/4885 |
| US-20100168188-A1 | Estrogen Receptor Modulators | ESR2, GPER1, ESRRA | KDM4E 1731/4885ALDH1A1 1883/4885KMT2A 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.